“Good to see [the] Biden administration changing course and making AstraZeneca vaccine available to India and others. Yes, should have happened sooner, but better late than [never.] Hope it is indicative of [a] larger shift in U.S. vaccine policy
away from sequentialism and toward simultaneity,” CFR President Richard N. Haass tweets.
“This is [a] great start. Now we need plans to
help make more vaccines, especially mRNA, to address the critical gaps in supply that remain,” CFR’s Jennifer Nuzzo tweets.